QOL Medical to Acquire Evoke Pharma for $6.35 Million

Evoke Pharma, Inc. (EVOK) entered a merger agreement on November 4, 2025, to be acquired by QOL Medical, LLC in an all-cash deal valued at $6.35 million

Deal Structure:

QOL Medical, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Evoke for $11 per share in cash, which is at a premium of 139.65% from the stock’s last close.

Company Profile:

Evoke Pharma is a specialty pharmaceutical company focused on developing and commercializing treatments for gastrointestinal disorders, including Gimoti, a nasal spray formulation of metoclopramide approved for the relief of symptoms associated with diabetic gastroparesis in adults.

QOL is a biopharmaceutical company that develops and sells treatments for rare and gastrointestinal diseases, focusing on medicines that serve small or underserved patient groups.

Deal Details and Timeline:

The deal is expected to close by the end of 2025.

Stifel served as financial advisor, and Latham & Watkins provided legal counsel to Evoke Pharma, while Hill Ward Henderson advised QOL Medical on legal matters.

The acquisition price values Evoke Pharma at 2.21 times its sales.

Deal Metrics:

For a comprehensive understanding of this merger and acquisition event, we invite you to visit the Deal Metrics page at the following link:

Deal Metrics for the acquisition of Evoke Pharma, Inc. (EVOK) by QOL Medical, LLC

The comprehensive Deal Metrics page for each merger or acquisition offers the following insights:

• Spread history chart of the merger from its announcement through to its completion or failure.
• Timely updates on every event as the merger progresses, including expiry of the HSR period, regulatory approvals, shareholder votes, etc.
• Latest news and SEC filings.
• A historical record of deal updates.
• And much more.

Disclaimer: We advise all readers to conduct their due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article